{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:42:49Z","timestamp":1782405769215,"version":"3.54.5"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,7,22]]},"abstract":"<jats:p>\n            Super bioavailability (SUBA) itraconazole (S-ITZ), which releases drug in the duodenum, and conventional itraconazole (C-ITZ), which releases drug in the stomach, were compared in two pharmacokinetic (PK) studies: a 3-day loading dose study and a 15-day steady-state administration study. These were crossover oral bioequivalence studies performed under fed conditions in healthy adult volunteers. In the loading dose study, C-ITZ (two doses of 100\u2009mg each) and S-ITZ (two doses of 65\u2009mg each) were administered three times daily for 3\u2009days and once on day 4 (\n            <jats:italic>n<\/jats:italic>\n            \u2009=\u200915).\n          <\/jats:p>","DOI":"10.1128\/aac.00400-20","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T13:01:12Z","timestamp":1590152472000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults"],"prefix":"10.1128","volume":"64","author":[{"suffix":"III","given":"George R.","family":"Thompson","sequence":"first","affiliation":[{"name":"UC Davis School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Sacramento, California, USA"},{"name":"UC Davis School of Medicine, Department of Medical Microbiology and Immunology, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Mayne Pharma, Inc., Raleigh, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Mudge","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Mayne Pharma, LLC, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, Division of Infectious Diseases, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce P.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Mayne Pharma, Inc., Raleigh, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01723-18"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01558-13"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00505.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00973-15"},{"key":"e_1_3_2_6_2","unstructured":"U.S. National Library of Medicine. 2020. Tolsura (SUBA-itraconazole 65 mg capsule). Accessed February 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861."},{"key":"e_1_3_2_7_2","unstructured":"U.S. FDA. 2020. Approval package for Tolsura (SUBA-itraconazole 65 mg capsule). Accessed February 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208901Orig1s000Approv.pdf."},{"key":"e_1_3_2_8_2","unstructured":"U.S. FDA. 1999. Guidance for industry applications covered by section 505(b)(2). Accessed February 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applications-covered-section-505b2."},{"key":"e_1_3_2_9_2","unstructured":"U.S. National Library of Medicine. 2020. Sporanox (itraconazole 100 mg capsule) prescribing information. Accessed February 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a4d555fa-787c-40fb-bb7d-b0d4f7318fd0."},{"key":"e_1_3_2_10_2","first-page":"193","volume-title":"Profiles of drug substances, excipients and related methodology","author":"Al-Badr AA","year":"2009","unstructured":"Al-Badr AA, El-Subbagh IE. 2009. Itraconazole: comprehensive profile, p 193\u2013264. In Brittain H (ed), Profiles of drug substances, excipients and related methodology, 1st ed, vol 35. Academic Press, New York, NY.","edition":"1"},{"key":"e_1_3_2_11_2","unstructured":"U.S. National Library of Medicine. 2020. Sporanox (itraconazole 10 mg\/mL solution) prescribing information. Accessed February 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ae50721d-ee15-4ee7-9fe7-afd98c56461b."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076530"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.052"},{"key":"e_1_3_2_14_2","unstructured":"Therapeutic Goods Administration. 2020. Lozanoc (itraconazole 50 mg capsule) prescribing information. Accessed February 2020. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2014-PI-01749-1&d=202001011016933."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz303"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.37.4.778"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558308"},{"key":"e_1_3_2_18_2","volume-title":"Infectious Disease Week","author":"Mudge S","year":"2019","unstructured":"Mudge S, Lewis P, Burnett BP. 2019. Relative bioavailability of single oral doses of SUBA-itraconazole 65mg capsule compared to conventional itraconazole 100mg capsule administered under fasted and fed conditions in healthy adult volunteers, poster 2229. Abstr Infectious Disease Week, Washington, DC."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.6.477"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704614"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00705-08"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809050939"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90023-X"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.35.4.707"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/605499"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.794785"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx295"},{"key":"e_1_3_2_28_2","unstructured":"U.S. National Library of Medicine. 2020. Endemic mycoses treatment with SUBA-itraconazole vs itraconazole (MSG15). Accessed February 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03572049?term=SUBA&draw=2&rank=2."},{"key":"e_1_3_2_29_2","volume-title":"Medical dictionary for regulatory activities","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2019","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2019. Medical dictionary for regulatory activities. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Geneva, Switzerland. https:\/\/www.ich.org\/."},{"key":"e_1_3_2_30_2","unstructured":"Chow SC Liu JP. 1992. Some related problems in bioavailability studies ch. 12. In Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker New York NY."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00400-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00400-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:40:14Z","timestamp":1645479614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00400-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,22]]}},"alternative-id":["10.1128\/AAC.00400-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00400-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"2020-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00400-20"}}